TVI-Brain-1 is under clinical development by TVAX Biomedical and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TVI-Brain-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TVI-Brain-1 is under development for the treatment of grade IV gliomas and glioblastoma. The therapeutic candidate is administered as intravenous infusion. It is developed based on TVAX immunotherapy platform that employs a unique combination of cancer cell vaccination and killer T-cell treatment.
It was in pediatrics for the treatment of high grade glioma
TVAX Biomedical overview
TVAX Biomedical is a company that develops drugs in the clinical stage cell-based on immunotherapy for treatment of cancer. It uses proprietary combination of cancer cell vaccination with killer T cell treatment. The company’s TVI-Brain-1 is a drug therapy used for the treatment of brain cancer. TVAX Biomedical is also developing therapy for treatment of kidney cancer. The company conducts clinical trials in key canine cancers to determine safety and usefulness of TVAX Immunotherapy as a treatment for wide range of canine cancer types. It also undertakes clinical trials for TVI-Kidney-1 to support its potential FDA approval. TVAX Biomedical is headquartered in Olathe, Kansas, the US.
For a complete picture of TVI-Brain-1’s drug-specific PTSR and LoA scores, buy the report here.